Advertisement


Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Advertisement